Peptide & Compound Guide
At a glance
| Compound | NAD+ |
|---|---|
| Type | Nicotinamide adenine dinucleotide; cellular coenzyme rather than a peptide |
| U.S. regulatory context | Not a peptide; therapeutic claims depend on product and route |
| Evidence level | Extensive basic biology; human intervention evidence varies |
| Research area | Cellular energy, redox biology, metabolism and aging research |
What is NAD+?
NAD+ is not a peptide, but it is frequently discussed alongside peptides in longevity communities. It is a core cellular coenzyme involved in energy metabolism and redox reactions.
What does the research examine?
Interest in NAD biology has led to research on precursors and interventions intended to influence NAD-related pathways. Changes in NAD biomarkers should be distinguished from proven improvements in healthspan or clinical outcomes.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Commercial longevity claims can move faster than clinical evidence. Product type, route and evidence should be evaluated separately.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.